Kornimate/medical-research-clean huggingface dataset:
using health information technology to improve health behaviors and promote cardiovascular health among adolescent and young adult cancer survivors

Conditions: Cardiovascular Disease; Young Adult Cancer Survivors

Summary: health information technology (hit) has the potential to improve the quality, efficiency, consistency, and availability of cancer survivor care. prevent is a novel hit tool designed by our team for adolescents (12-19 years). prevent aggregates and displays the american heart association's (aha) life simple 7 cardiovascular health (cvh) risk factors and provides tailored, evidence-based, behavior change recommendations inclusive of community resources that are delivered to overweight/obese adolescents at the point-of-care to improve cvh. the investigators seek to expand this tool for patients beyond 19 years of age to increase this tool's reach to the entire adolescent and young adult (aya) age range and then evaluate its effectiveness among aya cancer survivors.


Eligibility criteria:
patient eligibility criteria * aged 20-39 years * prior diagnosis of pediatric cancer (diagnosed \<21 years of age). * not receiving active therapy for their cancer * receiving care from the pediatric hematology/oncology staff and physicians at st. louis children's hospital, the st. louis children's specialty care center, siteman cancer center's lifelong outcomes clinic at siteman south county * at risk for poor cvh (bmi ≥ 25 kg/m\^2) * ability to understand and willingness to sign an irb approved written informed consent document (or that of legally authorized representative, if applicable). provider eligibility criteria. -all providers and clinic staff (physicians, nurses, clinic staff, clinic research associates) in the pediatric hematology/oncology program at st. louis children's hospital and the cscc or in the siteman cancer center's lifelong outcomes clinic at siteman south county are eligible to participate.
hybrid artificial pancreas in home setting

Conditions: Type 1 Diabetes Mellitus; Treatement by Insulin Pump

Summary: the primary purpose of this study is the evaluate an artificial pancreas during 2 months in home setting in type 1 diabetic patients

during this study, we propose to assess an artificial pancreas in a group of type 1 diabetic patients who will participate in two study periods of two-month duration with an insulin pump and a continuous glucose monitoring (cgm) device. during one of these periods, called hybrid period, the patient will use the ap model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and cgm for the rest of the day. during the control period called open period, patient self management of diabetes by insulin pump and cgm will be done at all times. overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 et \< 70 years old 2. having diabetes according to who criteria for at least 6 months, and type 1 diabetes according to ada criteria 3. under basal-bolus insulin therapy using an external insulin pump for at least 3 months 4. bmi \< 35 kg/m² 5. willing to wear a cgm device for the whole duration of the study, except during washout period, combined with the dias platform during the evening and night-time for 2 months 6. trained in carbohydrate counting 7. hba1c \> 7.5 % and \< 10% 8. if on antihypertensive, thyroid, anti-depressant or lipid lowering medication, stability on the medication for at least 1 month prior to study inclusion 9. willing to undergo all study procedures 10. informed consent signed exclusion criteria: 1. pregnancy or breast feeding, or intention to be pregnant during the study duration 2. use of a medication that significantly impacts glucose metabolism, e.g. steroids 3. uncontrolled hypertension with resting blood pressure over 140/90 mmhg 4. patient plans to go abroad during the trial period 5. patient is expected to be out-of-home in the evening and during night time (e.g. shift-workers, etc.) more than 25% of a study period 6. patient does not hold any nearby party for assistance if needed 7. patient with severe hypoglycemia including coma, mental confusion and/or convulsions requesting iv glucose injection or glucagon injection during the last year. 8. presence of any malignant disease, unless considered as cured for more than 10 years 9. history of acute cardiovascular event during the prior year 10. history of diabetic keto-acidosis during the prior 6 months 11. renal insufficiency with creatinin \> 150 μmol/l 12. impairment of liver status estimated from asat/alat plasma levels \> 2x upper limits of normal values 13. impaired cognitive or psychological abilities which may result in defective adherence to study conditions

Keywords: type 1 diabetes, t1dm, artificial pancreas
prevention of heterotopic ossification with arcoxia after total hip replacement

Conditions: Ossification, Heterotopic

Summary: the purpose of the study is to determine whether arcoxia is effective in preventing heterotopic ossification after total hip arthroplasty.

rationale: heterotopic ossification is a frequent complication after total hip replacement. nonsteroidal anti-inflammatory drugs (nsaids) are known to effectively prevent heterotopic ossification, but gastrointestinal complaints are reported frequently. selective cyclooxygenase-2 (cox-2) inhibiting nsaid produce less gastrointestinal side effects. objective: preventing heterotopic ossification. study design: a prospective two-stage study design for phase-2 clinical trials with 42 patients to determine if arcoxia (a cox-2 inhibitor) 90-mg oral prevents heterotopic ossification. in the first stage, 19-patients are included. another 23-patients are included when at least 90-percent of patients in first stage have brooker classification 0, 1 or 2 at 6-months follow-up. study population: 42-patients with cemented total hip arthroplasty age 18 - 75 yr old. intervention: all subjects receive 90-mg arcoxia oral for 7-days. main study parameters/endpoints: the main study parameter is the degree of heterotopic ossification assessed on ap radiographs using the brooker classification. nature and extent of the burden and risks associated with participation, benefit and group relatedness: no risks are associated with participating into the research. besides the oral intake of arcoxia, no extra burden is associated with participating in the study. the postoperative care does not change. radiographic examinations will be routinely performed the day before surgery, immediately after operation, at 6-weeks and 6-months after surgery. the degree of heterotopic ossification will be determined by x-ray assessment.

Eligibility criteria:
inclusion criteria: * patients with primary or secondary hip osteoarthritis who are scheduled for cemented total hip replacement at the radboud university nijmegen medical centre, nijmegen, the netherlands. * written informed consent is obtained from the patient or the legally accepted representative. exclusion criteria: * patients with rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures * patients with previous allergic reaction on non-steroidal anti-inflammatory drugs * patients with gastrointestinal complaints at admission, a history of gastrointestinal ulcers or perforations, inflammatory bowel-disease, hepatic dysfunction, renal dysfunction with a clearance below 30 ml/min and cardiac insufficiency. * patients with blood pressure consistently \> 140/90 mmhg and who have not been adequately controlled.

Keywords: arthroplasty hip cemented heterotopic ossification selective cyclooxygenase-2 inhibitors arthroplasty, replacement hip prosthesis cyclooxygenase inhibitors
radiological and clinical outcome after screw osteosynthesis of radial head fractures

Conditions: Radial Head Fractures

Summary: this cohort study investigates radiological and clinical outcome after screw osteosynthesis of radial head fractures with associated injuries (such as rupture of the interosseous membrane and collateral ligaments). interpretation of radiographs 3 and 9 months post- surgery and patient surveys will be analyzed.


Eligibility criteria:
inclusion criteria: * screw osteosynthesis of radial head fractures exclusion criteria: * unable to give consent * dementia

Keywords: screw osteosynthesis rupture of the interosseous membrane collateral ligaments
usability of hpv vaccine reminders

Conditions: Human Papilloma Virus (HPV)

Summary: this study will assess the usefulness of parent-targeted strategies in improving care seeking among parents of 11-12 year old adolescents. specifically, the study team will focus on reminders (postcard or text message) and motivational interviewing to improve adolescent vaccination.

despite the impressive cancer preventing potential of human papillomavirus (hpv) vaccines, hpv vaccine coverage rates in the united states remain substantially lower than other vaccines and healthy people 2020 targets. hpv vaccine initiation can be improved through targeted reminders that motivate parents. our long-term goal is to maximize hpv vaccination rates among girls and boys within the united states using efficient and sustainable strategies. the objective of this protocol is to evaluate the usefulness of a tiered strategy of a parent-targeted strategies in improving care seeking and receptiveness to vaccine recommendations. strategies include hpv vaccine reminders via postcard or text message and phone-based motivational interview sessions. the central hypothesis is addressing key health beliefs (e.g., perceived benefits and barriers) will increase parental acceptance and, thus, hpv vaccine initiation.

Eligibility criteria:
inclusion criteria: * parents of 11-12 year olds who attend the schiebler cms clinic at university of florida in the previous year exclusion criteria: * unable to meet inclusion criteria

Keywords: vaccine
assessing the cortical response to noxious and auditory stimuli using near infrared spectroscopy in subjects under general anesthesia

Conditions: Anesthesia; Pain

Summary: the primary aim is to utilize near-infrared spectroscopy (nirs) in patients under general anesthesia to measure changes in brain blood flow in the bilateral somatosensory cortices and the prefrontal cortices in response to noxious stimulation.


Eligibility criteria:
inclusion criteria: * 12-30 years of age * structurally normal heart * right-handed * english-speaking exclusion criteria: * unable to cooperate or understand the study * neurologic disease * diabetes mellitus * syndrome of greater than minor severity. * smoker * scalp or hair does not permit sufficient optical light detection * unable to keep his/her head still for a period of 200 consecutive seconds
arabic version of marx activity rating and knee stability in sports/cutting-pivoting ability scales

Conditions: Anterior Cruciate Ligament; Injuries

Summary: anterior cruciate ligament (acl) injuries are among the most common knee ligament injuries, causing joint instability and impairments. besides being challenging, this type of injury greatly affects the athlete's passion and wellbeing, and it is associated with several risk factors. injuries to the acl are estimated to occur within 80,000 to 250,000 young, active and healthy athletes each year. this cross-sectional observational study aimed at translating, adapting cross-culturally, and investigating the psychometric properties of the marx activity rating scale (mars) and the knee stability in sports/cutting-pivoting ability (kss/cpa) scale in saudi patients with anterior cruciate ligament injuries. for this study, a convenient sample size of 100 athletes with acl injuries and healthy participants will be selected from different saudi hospitals and clubs. study participants will be informed about the study and a consent form will be obtained before they participate. a number of scales will be used as outcome measures, including the mars, kss/cpa scale, knee injury, and osteoarthritis outcome score, lysholm knee score, and international knee documentation committee subjective knee form. internal consistency of both the mars and kss/cpa scales will be tested using cronbach's alpha. a construct's validity will be measured by spearman's correlation coefficient. content validity can be determined by examining whether there are floor and ceiling effects. a significance level of 0.05 will be used to determine whether the data is significant. ultimately, the study will help patients with acl injuries to make informed decisions about their treatment, empower healthcare professionals to understand patients' concerns, and facilitate research.


Eligibility criteria:
inclusion criteria: 1. an athlete with an orthopedic diagnosis of unilateral acl injury 2. age from 18 years to 45 years old 3. participants who read and write in arabic 4. healthy participants that do not have lower limb injury limited participation in physical activity for at least six months. exclusion criteria: * 1 patients with other lower limbs or different musculoskeletal injuries such as lower back pain may affect physical activity

Keywords: knee injury sports ability activity level patient report outcome rating scales
evaluating the effectiveness and outcomes of silicone breast prosthetics

Conditions: Breast Cancer

Summary: this trial will evaluate the outcome of placement of silicone breast prosthetics.

patients will be evaluated for complications following placement of silicone breast prostheses.

Eligibility criteria:
inclusion criteria: * over 18 undergoing breast reconstruction exclusion criteria: * patients with collagen vascular diseases, rheumatoid arthritis, scleroderma, etc. study closed

Keywords: breast, reconstruction, silicone
perfenidone in type 2 diabetic patients with diabetic neuropathy

Conditions: Diabetic Nephropathies; Type 2 Diabetes

Summary: the purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy


Eligibility criteria:
inclusion criteria: * diabetic nephropathy stage 3 (egfr 30-59 ml/min/1.73m2) type 2 diabetes hba1c \<7.5% patient taking acei/arb for at least 3 months bp \<140/90 exclusion criteria: * history of photosensitivity rash history of decompensated liver or cardiac disease history of urinary tract infection pregnancy or lactation history of nephrotoxic drugs or hakeem medication polycystic kidney disease history of autoimmune disease history of hypersensitivity to study drugs

Keywords: type 2 diabetes mellitus diabetic nephropathy perfenidone
construction of diagnosis and treatment system for primary vitreoretinal lymphoma

Conditions: Primary Vitreoretinal Lymphoma

Summary: this study intends to apply for the establishment of research beds, establish a chinese pvrl research cohort, and carry out a to achieve the following research objectives: the goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma（pvrl）. the study is to achieve the following research objectives: 1. to establish a comprehensive diagnostic criteria for pvrl with high diagnostic efficiency and strengthen the pvrl diagnostic system; 2. to establish a standardized treatment pathway for pvrl and evaluate the efficacy and safety of treatment; 3. to screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of pvrl； 4. to explore the pathogenesis of pvrl, specific tumor markers and drug therapeutic targets.


Eligibility criteria:
inclusion criteria: * newly diagnosed pvrl patients admitted to the ophthalmology or hematology departments of peking union medical college hospital from 2022 to 2024; * 18-75 years old; * the diagnosis was confirmed by pathology, aqueous humor/vitreous il-10/il-6, vitreous flow cytometry and gene rearrangement.; * hiv-ab negative; * creatinine clearance \> 50ml/min; * sign informed consent. exclusion criteria: * combined with other tumors; * uncontrolled active infections; * pregnant or lactating women; * antitumor therapy other than the protocol of this study was used.
bariatric surgery and pharmacokinetics of methylphenidate

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study we investigate the pharmacokinetic effects of bariatric surgery on methylphenidate.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics methylphenidate
autism alert expansion

Conditions: Autism Spectrum Disorder

Summary: autism access link for early referral and treatment \[alert\], the intervention proposed in this application, is a novel state-wide referral and case management platform that pcps can activate to ensure that a child with suspected asd receives all necessary asd diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process. we hypothesize that autism alert will have strong acceptability and high rates of use among primary care providers as well as among diverse low-income parents of children at risk for asd, and that we will see increased rate of child asd educational evaluations within six months, and shortened time between referral and asd treatment.

though significant research effort has focused on autism spectrum disorder (asd) screening, less attention has been devoted to optimizing follow-up of children who are subsequently identified as at-risk. despite increases in asd screening rates, many children with asd wait years between when autism is suspected in the primary care setting and when definitive diagnosis and treatment begin. delayed and missed diagnoses are particularly problematic for low-income and racial/ethnic minority children in the us, who experience higher rates of these adverse outcomes. the autism access link to early referral and treatment (autism alert) program is a statewide monitoring and case management program to accelerate access to asd diagnosis and treatment among children with suspected asd the primary care setting. the system will reduce the time between identification of suspected asd in the primary care setting and establishment of asd diagnosis and treatment services, by reducing family barriers to care, decreasing primary care provider burdens, and simplifying referral processes. following an initial pilot trial, we propose implementing the intervention to families in the portland metropolitan area before expanding the program elsewhere in the state. the program will be available to any oregon child age 12-54 months, regardless of health system or payor type. autism alert will become part of the help me grow national network, which gives it potential for statewide and national spread. in this proposed research, we will undertake a single arm implementation/effectiveness trial in which the program will be tested throughout the state of oregon, beginning in the portland metropolitan area. in the long term, this research will result in a sustainable, evidence-based statewide and ultimately national monitoring system children with suspected asd.

Eligibility criteria:
inclusion criteria: * child's primary care provider suspects the child has asd * child is a patient at one of the study clinics * child age 12 to 54 months * family speaks english or spanish * no prior asd medical diagnosis or asd diagnostic evaluation exclusion criteria: - previous diagnosis of asd or prior diagnostic evaluation for asd.

Keywords: autism spectrum disorder primary care case management
extension of phase 3 gene therapy for painful diabetic neuropathy

Conditions: Painful Diabetic Neuropathy; Diabetic Neuropathy, Painful

Summary: the purpose of this study is to explore the overall safety profile and durability of efficacy of engensis (vm202) in painful diabetic peripheral neuropathy. all subjects still in follow-up for the vmdn-003 study or who have completed the day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.

in the phase iii vmdn-003 study, subjects received 2 treatments of either engensis (vm202) or placebo administered as intramuscular injections into bilateral calves on days 0 and 14, and days 90 and 104. primary efficacy was evaluated 90 days following the first injection. the growth potential for hepatocyte growth factor make long-term follow-up important both for safety and efficacy: in order for engensis to be a candidate for chronic treatment of painful diabetic peripheral neuropathy, it must be demonstrated not to induce unexpected adverse events with repeated dosing; and the potential for reversal or stabilization of diabetic neuropathy using only one or two treatments of engensis may make it especially attractive compared to current treatments which must be taken daily for the duration of the disease. a safety extension to the vmdn-003 study is therefore warranted.

Eligibility criteria:
inclusion criteria: 1. were randomized and dosed in the vmdn-003 study 2. received all intramuscular injections of study drug on days 0, 14, 90, and 104 in the vmdn-003 study 3. were in follow-up for the vmdn-003 study or had completed day 270 within the last 90 days prior to signing consent exclusion criteria: 1. were using an investigational drug or treatment 2. were unable or unwilling to give informed consent

Keywords: diabetic neuropathy shooting pain burning pain pins and needles pain foot pain viromed helixmith engensis vm202